Background: Personality is considered as an important aspect in persons with psychotic disorders. Several studies have investigated personality in schizophrenia. However, no study has investigated stability of personality traits exceeding three years in patients with schizophrenia. This study aims to investigate the stability of personality traits over a five-year period among patients with schizophrenia and non-psychotic individuals and to evaluate case-control differences.
Methods: Patients with psychotic disorders (n = 36) and non-psychotic individuals (n = 76) completed Swedish universities Scales of Personality (SSP) at two occasions five years apart. SSP scores were analysed for effect of time and case-control differences by multiple analysis of covariance (MANCOVA) and within-subjects correlation.
Results: MANCOVA within-subjects analysis did not show any effect of time. Thus, SSP mean scale scores did not significantly vary during the five-year interval. Within subject correlations (Spearman) ranged 0.30-0.68 and 0.54-0.75 for the different SSP scales in patients and controls, respectively. Patients scored higher than controls in SSP scales Somatic Trait Anxiety, Psychic Trait Anxiety, Stress Susceptibility, Lack of Assertiveness, Detachment, Embitterment, and Mistrust.
Conclusion: The stability of the SSP personality trait was reasonably high among patients with psychotic disorder, although lower than among non-psychotic individuals, which is in accordance with previous research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389041 | PMC |
http://dx.doi.org/10.1186/s12888-018-1617-y | DOI Listing |
Background: Psychotic symptoms may manifest in Alzheimer's disease (AD), especially in advanced disease stages and in patients with higher polygenic risk scores for schizophrenia (SCZ-PRS). Such genetic risk seems also to influence grey matter volume (GMV) alterations in patients with psychosis. Since multiple neurotransmitter systems, namely dopamine (DA) and serotonin (5-HT), have been implicated in psychosis, the aim of this study was to investigate whether a SCZ-PRS may explain variance in the association between GMV and the cerebral distribution of DA and 5-HT.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
December 2024
Mental Health Research Centre, Moscow, Russia.
Objective: Identification of therapeutic targets in the treatment of adolescent depression with attenuated symptoms of schizophrenia and assessment of the effectiveness of therapeutic interventions.
Material And Methods: One hundred and twenty-three patients (mean age 19.6±2.
Arch Psychiatr Nurs
December 2024
Clinical Neuroscience Laboratory (NICE), REGNE Research Laboratory, Faculty of Medicine and pharmacy, Ibn Zohr University, Agadir, Morocco.
Background: Medication non-adherence in schizophrenia is a major cause of relapse and hospitalization, presenting a significant challenge for clinicians. This study was conducted to estimate the prevalence of medication non-adherence and identify the impact of depression, as well as other factors, on medication adherence in individuals with schizophrenia.
Methods: This was a cross-sectional study conducted among individuals with schizophrenia, both outpatients and inpatients.
Early Interv Psychiatry
November 2024
Mental Health Organization 'GGZ Oost Brabant', Centre for Eating Disorders, Helmond, The Netherlands.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!